Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8  +  and CD4  +  CD19-specific chimeric antigen receptor–modified T cells

Turtle, Cameron J.; Hanafi, Laïla‐Aïcha; Berger, Carolina; Hudecek, Michael; Pender, Barbara; Robinson, Emily; Hawkins, Reed M.; Chaney, Colette; Cherian, Sindhu; Chen, Xueyan; Soma, Lorinda; Wood, Brent L.; Li, Daniel; Heimfeld, Shelly; Riddell, Stanley R.; Maloney, David G.

doi:10.1126/scitranslmed.aaf8621

articleScience Translational MedicineSep 7, 2016Closed access

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells

CJCameron J. Turtle LHLaïla‐Aïcha Hanafi CBCarolina Berger MHMichael Hudecek BPBarbara Pender

University of Washington · Fred Hutch Cancer Center

PubMed

Indexed incrossrefpubmed

Abstract

CD19-specific chimeric antigen receptor (CAR)-modified T cells have antitumor activity in B cell malignancies, but factors that affect toxicity and efficacy have been difficult to define because of differences in lymphodepletion and heterogeneity of CAR-T cells administered to individual patients. We conducted a clinical trial in which CD19 CAR-T cells were manufactured from defined T cell subsets and administered in a 1:1 CD4(+)/CD8(+) ratio of CAR-T cells to 32 adults with relapsed and/or refractory B cell non-Hodgkin's lymphoma after cyclophosphamide (Cy)-based lymphodepletion chemotherapy with or without fludarabine (Flu). Patients who received Cy/Flu lymphodepletion had increased CAR-T cell expansion and…

Citation impact

1,006

total citations

FWCI: 55.02
Percentile: 100%
References: 38

Citations per year

Authors

16

Topics & keywords

Topics

Keywords

Medicine
Fludarabine
Cyclophosphamide
Chimeric antigen receptor
Cytokine release syndrome
Immunology
CD8
Immunotherapy

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.